SLC5A2 and type 2 diabetes mellitus: The PRESERVED-HF trial was designed to address this important knowledge gap by testing the hypothesis that treatment with the SGLT2 inhibitor dapagliflozin will improve symptoms, physical limitations and exercise function in patients with well-phenotyped HFpEF, both with and without type 2 diabetes (T2D).